Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report
- Authors:
- Ilaria Marech
- Angelo Vacca
- Nicola Sivestris
- Antonio Gnoni
- Vito Lorusso
View Affiliations
Affiliations: Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy, Medical Oncology Unit, National Cancer Research Centre, Giovanni Paolo II Tumor Institute, Bari, Italy, Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
- Published online on: March 29, 2013 https://doi.org/10.3892/ol.2013.1275
-
Pages:
1877-1880
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Docetaxel is the current first-line treatment for castration-resistant prostate cancer (CRPC), following failure to respond to maximal androgen blockade (MAB). Patients who fail to respond to docetaxel may receive cabazitaxel or abiraterone; however, there are no recommendations on which of these two agents should be used first. Here, we present a case of a male patient suffering from CRPC with liver and lymph node metastases, in which abiraterone achieved a partial response, according to RECIST criteria. In the literature, visceral involvement in patients with advanced prostate cancer is an infrequent occurrence; it affects 18‑22% of patients. In the pivotal study concerning docetaxel-resistant patients, abiraterone was compared with a placebo and the forest plot for survival demonstrated that patients with visceral involvement have significantly benefited from abiraterone. In the TROPIC trial comparing cabazitaxel with mitoxantrone, the proportion of patients with visceral disease was ~25% in both arms and there was no difference in overall survival in this subgroup of patients. In our case, we observed a significant activity of abiraterone in lymph node and liver metastases. If confirmed in large studies, this observation may raise concerns over whether to treat patients suffering from CRPC and visceral metasis with chemotherapy or hormone therapy.
View References
|
1
|
Siegel R, Desantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arcangeli S, Pinzi V and Arcangeli G:
Epidemiology of prostate cancer and treatment remarks. World J
Radiol. 4:241–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh SM, Gauthier S and Labrie F:
Androgen receptor antagonists (antiandrogens): structure-activity
relationships. Curr Med Chem. 7:211–224. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tannock IF, de Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petrylak DP, Tangen CM, Hussain MH, et al:
Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Bono JS, Oudard S, Ozguroglu M, et al:
Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: a randomised open-label trial. Lancet. 376:1147–1154.
2010.
|
|
7
|
De Bono JS, Logothetis CJ, Molina A, et
al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011.
|
|
8
|
Attard G, Reid AH, Olmos D and de Bono JS:
Antitumor activity with CYP17 blockade indicates that
castration-resistant prostate cancer frequently remains hormone
driven. Cancer Res. 69:4937–4940. 2009. View Article : Google Scholar
|
|
9
|
Attard G, Reid AH, A’Hern R, et al:
Selective inhibition of CYP17 with abiraterone acetate is highly
active in the treatment of castration- resistant prostate cancer. J
Clin Oncol. 27:3742–3748. 2009. View Article : Google Scholar
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
11
|
Ryan CJ; Helen Diller Family Comprehensive
Cancer Center, University of California, San Francisco, CA: Interim
analysis (IA) results of COU-AA-302, a randomized, phase 3 study of
abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with
metastatic castration-resistant prostate cancer (mCRPC). (Abstract
LBA 4518) ASCO. 2012.
|
|
12
|
Mezynski J, Pezaro C, Bianchini D, et al:
Antitumour activity of docetaxel following treatment with the
CYP17A1 inhibitor abiraterone: clinical evidence for
cross-resistance? Ann Oncol. July 5–2012.(E-pub ahead of print).
View Article : Google Scholar
|
